Current Report Filing (8-k)
February 03 2017 - 7:48AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February
3,
2017 (February 2, 2017)
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-3619
|
13-5315170
|
(State or other Jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
235 East 42nd Street
New York, New York
(Address of principal executive offices)
|
|
10017
(Zip Code)
|
Registrant's telephone number, including area code:
(212) 733-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.0
1
|
Other Events
|
On February 2, 2017, Pfizer Inc. ("Pfizer") entered into an accelerated
share repurchase agreement with Citibank N.A. ("Citibank") to repurchase $5 billion of
Pfizer's common stock. Approximately 126 million of the shares to be
repurchased under the transaction will be received by Pfizer on February 6,
2017.
At settlement of the agreement, which is expected to occur
during or prior to the third quarter of 2017, Citibank may be required to deliver
additional shares of Pfizer's common stock to Pfizer, or, under certain
circumstances, Pfizer may be required to deliver shares of its common stock
or may elect to make a cash payment to Citibank, with the number of shares to
be delivered or the amount of such payment based on the volume-weighted average price of
Pfizer's common stock during the term of the transaction.
This
agreement was entered into pursuant to Pfizer's previously announced share
repurchase authorization.
The press release relating to the
accelerated share repurchase agreement is filed as an exhibit to this Form
8-K and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d) Exhibits
|
|
|
|
|
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release of Pfizer Inc. dated February 3, 2017
|
|
|
|
|
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
|
|
PFIZER INC.
|
|
|
|
|
|
By:
/s/ Margaret M. Madden
Margaret M. Madden
|
|
|
Title: Vice President and Corporate Secretary
|
Dated: February 3, 2017
|
|
Chief Governance Counsel
|
EXHIBIT INDEX
Number
|
Description
|
99.1
|
Press Release of Pfizer Inc. dated February 3, 2017
|
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024